Roche Holding AG and Isis Pharmaceuticals, Inc. announced, earlier this month, that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
http://www.sbwire.com/press-releases/daily-trend-analysis-report-on-otcrhhby-pinknsrgy-239959.htm
http://www.sbwire.com/press-releases/daily-trend-analysis-report-on-otcrhhby-pinknsrgy-239959.htm
No comments:
Post a Comment